Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
This article was originally published in The Pink Sheet Daily
Industry and FDA are in the process of ratifying the commitment letter for BsUFA II, leaving only the generic drug user fee program still ongoing.
You may also be interested in...
A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.
Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.
Generics industry and FDA have resolved remaining issues regarding financing of user fee program.